Ipsen S.A. (LON:0MH6)

London flag London · Delayed Price · Currency is GBP · Price in EUR
103.20
0.00 (0.00%)
At close: Jul 8, 2025
-5.74%
Market Cap 7.70B
Revenue (ttm) 2.96B
Net Income (ttm) 286.05M
Shares Out n/a
EPS (ttm) 3.43
PE Ratio 26.91
Forward PE 10.36
Dividend 1.18 (1.14%)
Ex-Dividend Date Jun 4, 2025
Volume 8,002
Average Volume 42,682
Open 102.25
Previous Close 103.20
Day's Range 102.30 - 103.20
52-Week Range 88.05 - 125.35
Beta 0.19
RSI 67.63
Earnings Date Jul 31, 2025

About Ipsen

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical t... [Read more]

Industry Pharmaceutical Preparations
Founded 1929
Employees 5,358
Stock Exchange London Stock Exchange
Ticker Symbol 0MH6
Full Company Profile

Financial Performance

In 2024, Ipsen's revenue was 3.57 billion, an increase of 8.11% compared to the previous year's 3.31 billion. Earnings were 345.90 million, a decrease of -46.32%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.